Sosum S — LTSR HA Filler for Fine Lines (Lidocaine-Free, 2 x 1ml)

Sosum S is JSBIO’s lightest variant — 20 mg/mL cross-linked HA produced via patented LTSR (Low-Temperature Stabilization Reaction) technology with zero residual BDDE. Lidocaine-free formulation for practitioners managing separate anaesthesia. Engineered for superficial dermal placement targeting fine lines, forehead, and neck wrinkles. 2 x 1 mL pack with JBP nanoneedles included.

Sosum S Fine Lines Dermal Filler is manufactured by JSBIO Co. Ltd., a South Korea-based medical device and pharmaceutical company established in 2013. The product is part of the Sosum dermal filler range, which is distributed across multiple international markets. Regulatory status: MFDS approval 2013 · CE certified · GMP.

Sosum S Fine Lines Dermal Filler contains 20 mg/mL of cross-linked hyaluronic acid plus 0.3% (3 mg/mL) premixed lidocaine for injection comfort. The hyaluronic acid is non-animal, produced by bacterial fermentation and cross-linked using JSBIO Co. Ltd.’s Low-Temperature Stabilization Reaction Technology technology. Phosphate-buffered saline at near-physiological pH carries the gel.

Per JSBIO Co. Ltd.’s clinical data, Sosum S Fine Lines Dermal Filler delivers Up to 12 months of correction depending on placement and patient factors. Duration depends on injection depth, dose, anatomical site, patient metabolism, and facial movement intensity. Superficial dermis placement typically delivers the longer end of the duration range.

Sosum S Fine Lines Dermal Filler is engineered for superficial dermis placement. The standard recommended needle is 30G + JBP nanoneedles, supplied in the syringe blister pack. Some practitioners prefer a blunt-tip cannula of equivalent gauge for safer placement in highly vascular zones, particularly for deeper subcutaneous work.

Sosum S Fine Lines Dermal Filler regulatory status: MFDS approval 2013 · CE certified · GMP. The product’s KFDA registration in South Korea is the primary regulatory baseline. CE marking and other international approvals enable distribution in the EU and other regulated markets. US FDA status varies — buyers in regulated jurisdictions should verify approval scope before importation and clinical use.

Store Sosum S Fine Lines Dermal Filler between 2 °C and 25 °C in original packaging, away from direct sunlight. Do not freeze — freezing damages the HA gel structure. Shelf life is typically 24 months from the manufacturing date printed on the box when unopened. Once a syringe is opened, contents must be used immediately. Partial syringes cannot be retained for later use due to sterility risk.

No. Sosum S Fine Lines Dermal Filler uses non-animal hyaluronic acid produced by bacterial fermentation — the standard manufacturing approach for modern HA dermal fillers. The product contains no animal proteins or by-products, making it suitable for patients who avoid animal-derived medical products. The product is contraindicated in patients with severe allergies to gram-positive bacterial proteins (used in HA fermentation).

Yes — layered protocols combining different fillers are standard aesthetic practice. Sosum S Fine Lines Dermal Filler can be combined with other Korean or international HA fillers, neuromodulators (botulinum toxin), or biostimulators (PLLA, calcium hydroxylapatite) within a single session. Always wait the recommended interval between different injectable products and confirm biocompatibility per each manufacturer’s IFU.

JSBIO supplies the entire Sosum range without integrated lidocaine to serve practitioners who prefer separate anaesthesia control — for example, combining filler placement with topical anaesthesia, nerve blocks, or to support patients with documented lidocaine sensitivity. The lidocaine-free formulation also supports the no-needle (cannula) injection technique that some practitioners use with Sosum. Each box includes JBP nanoneedles for precise placement. For practitioners requiring premixed lidocaine, alternative Korean HA fillers like Bellast or Bonetta include 0.3% lidocaine.